Compare · LLY vs ONTX
LLY vs ONTX
Side-by-side comparison of Eli Lilly and Company (LLY) and Onconova Therapeutics Inc. (ONTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and ONTX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.35T.
- LLY has hit the wire 31 times in the past 4 weeks while ONTX has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 1 for ONTX).
- Company
- Eli Lilly and Company
- Onconova Therapeutics Inc.
- Price
- -
- -
- Market cap
- $1.35T
- -
- 1M return
- +14.06%
- -
- 1Y return
- +40.42%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 31
- 0
- Recent ratings
- 25
- 1
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Onconova Therapeutics Inc.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.
Latest LLY
- Stocks Carry Weekly Gains Into a Wall of Chart Resistance as Volatility Cools
- Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
- Weekly Gains Hold Up Despite a Friday Slide as Chips Lead and Yields Climb
- Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
- Nasdaq Jumps Over 4% This Week as Chip Names Drive a Sharp Midweek Rally
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
- EVP & President, LLY Int'l Jonsson Patrik gifted 704 shares, decreasing direct ownership by 1% to 53,443 units (SEC Form 4)
- Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
- Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
Latest ONTX
- SEC Form 10-K/A filed by Onconova Therapeutics Inc. (Amendment)
- SEC Form D filed by Onconova Therapeutics Inc.
- SEC Form DEFA14A filed by Onconova Therapeutics Inc.
- Onconova Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- New insider Orbimed Advisors Llc claimed ownership of 1,045,261 shares (SEC Form 3) (Amendment)
- New insider Tpav, Llc claimed ownership of 1,222,738 shares (SEC Form 3) (Amendment)
- SEC Form SC 13D filed by Onconova Therapeutics Inc.
- Redfield Robert was granted 97,500 shares (SEC Form 4)
- Pauza Charles David was granted 97,500 shares (SEC Form 4)
- Cautreels Werner was granted 200,000 shares (SEC Form 4)